Literature DB >> 8950681

Disrupted growth plates and progressive deformities in osteogenesis imperfecta as a result of the substitution of glycine 585 by valine in the alpha 2 (I) chain of type I collagen.

W G Cole1, D Chan, C W Chow, J G Rogers, J F Bateman.   

Abstract

The skeleton of a child with osteogenesis imperfecta type III, resulting from the substitution of glycine 586 by valine in the triple helical domain of the alpha 2 (I) chain of type I collagen, was severely porotic but contained lamellar bone and Haversian systems. From early childhood, structural failure of the bone resulted in the disruption of growth plates, progressive bone deformities, and severe growth retardation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8950681      PMCID: PMC1050795          DOI: 10.1136/jmg.33.11.968

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  18 in total

1.  A dominant mutation in the COL1A1 gene that substitutes glycine for valine causes recurrent lethal osteogenesis imperfecta.

Authors:  J Bonaventure; L Cohen-Solal; C Lasselin; P Maroteaux
Journal:  Hum Genet       Date:  1992-08       Impact factor: 4.132

Review 2.  Osteogenesis imperfecta: translation of mutation to phenotype.

Authors:  P H Byers; G A Wallis; M C Willing
Journal:  J Med Genet       Date:  1991-07       Impact factor: 6.318

3.  RNA sequence analysis of a perinatal lethal osteogenesis imperfecta mutation.

Authors:  E Patterson; E Smiley; J Bonadio
Journal:  J Biol Chem       Date:  1989-06-15       Impact factor: 5.157

4.  Osteogenesis imperfecta type III. Delineation of the phenotype with reference to genetic heterogeneity.

Authors:  D O Sillence; K K Barlow; W G Cole; S Dietrich; A P Garber; D L Rimoin
Journal:  Am J Med Genet       Date:  1986-03

5.  Collagen defects in lethal perinatal osteogenesis imperfecta.

Authors:  J F Bateman; D Chan; T Mascara; J G Rogers; W G Cole
Journal:  Biochem J       Date:  1986-12-15       Impact factor: 3.857

6.  A novel G1006A substitution in the alpha 2(I) chain of type I collagen produces osteogenesis imperfecta type III.

Authors:  J Lu; T Costa; W G Cole
Journal:  Hum Mutat       Date:  1995       Impact factor: 4.878

7.  Characterization of a type I collagen alpha 2(I) glycine-586 to valine substitution in osteogenesis imperfecta type IV. Detection of the mutation and prenatal diagnosis by a chemical cleavage method.

Authors:  J F Bateman; M Hannagan; D Chan; W G Cole
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

8.  The clinicopathological features of three babies with osteogenesis imperfecta resulting from the substitution of glycine by valine in the pro alpha 1 (I) chain of type I procollagen.

Authors:  W G Cole; E Patterson; J Bonadio; P E Campbell; D W Fortune
Journal:  J Med Genet       Date:  1992-02       Impact factor: 6.318

9.  Genetic heterogeneity in osteogenesis imperfecta.

Authors:  D O Sillence; A Senn; D M Danks
Journal:  J Med Genet       Date:  1979-04       Impact factor: 6.318

10.  Characterization of point mutations in the collagen COL1A1 and COL1A2 genes causing lethal perinatal osteogenesis imperfecta.

Authors:  S R Lamande; H H Dahl; W G Cole; J F Bateman
Journal:  J Biol Chem       Date:  1989-09-25       Impact factor: 5.157

View more
  2 in total

1.  CRTAP mutations in lethal and severe osteogenesis imperfecta: the importance of combining biochemical and molecular genetic analysis.

Authors:  Fleur S Van Dijk; Isabel M Nesbitt; Peter G J Nikkels; Ann Dalton; Ernie M H F Bongers; Jiddeke M van de Kamp; Yvonne Hilhorst-Hofstee; Nicolette S Den Hollander; Augusta M A Lachmeijer; Carlo L Marcelis; Gita M B Tan-Sindhunata; Rick R van Rijn; Hanne Meijers-Heijboer; Jan M Cobben; Gerard Pals
Journal:  Eur J Hum Genet       Date:  2009-06-24       Impact factor: 4.246

2.  Alterations of a serum marker of collagen X in growing children with osteogenesis imperfecta.

Authors:  L E Nicol; R F Coghlan; D Cuthbertson; Sandesh C S Nagamani; B Lee; R C Olney; W Horton; E Orwoll
Journal:  Bone       Date:  2021-04-28       Impact factor: 4.626

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.